CINGULATE INC. news, videos and press releases
For more news please use our advanced search feature.
CINGULATE INC. - More news...
CINGULATE INC. - More news...
- FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
- Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
- Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
- Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
- Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
- Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
- Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
- Final Study Completed for Cingulate’s Lead Asset CTx-1301
- Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
- Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
- Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
- Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate Announces Adjournment of Special Meeting
- Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
- Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
- Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
- Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
- Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
- FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
- Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
- Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
- Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
- Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate to Attend DCAT Week 2024 in New York City
- Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
- Cingulate Announces Closing of $7.5 Million Public Offering
- Cingulate Announces Pricing of $7.5 Million Public Offering
- Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
